Journal article
How to reverse bleeding in patients on direct oral anticoagulants?
Abstract
The direct oral anticoagulants (DOACs), or non-vitamin K antagonist oral anticoagulants (NOACs), including dabigatran, which inhibits thrombin, as well as rivaroxaban, apixaban, edoxaban, and betrixaban, which inhibit coagulation factor Xa, are as-sociated with similar or lower risk of bleeding compared with warfarin. The need for reversal of their anticoagulant effect may occur in patients with life-threatening bleeding or those requiring …
Authors
Crowther M; Cuker A
Journal
Kardiologia Polska, Vol. 77, No. 1, pp. 3–11
Publisher
Polskie Towarzystwo Kardiologiczne
Publication Date
2019
DOI
10.5603/kp.a2018.0197
ISSN
0022-9032